Malignant Hyperthermia Status in China

Belani, Kumar G.; Cao, Cathy; Daugherty, Dianne; Guo, Xiangyang; Hu, Ling; Huang, Jiapeng; Liu, Henry; Litman, Ronald S.; Rosenberg, Henry; Stellaccio, Francis S.; Wei, Huafeng; Yu, Shuchun; Zhang, Xiaoyan; Zuo, Yunxia

doi:10.1213/ane.0000000000001043

Cited by 8 publications

(10 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…8,11,12 Previous studies indicated the mortality rate of MH in China could be as high as 73.5%. 10,13,14 The striking high mortality may be due to the fact that few hospitals in China stored dantrolene. 10 On the other hand, there is a major shortage of MH-related resources and most anesthesiologists have never received MH simulation training.…”

Section: Introductionmentioning

confidence: 99%

“…Hence, anesthesiologists lack certain stock of MH relevant theoretical knowledge and are inexperienced in face of MH crisis. 14 Moreover, owing to lack of professional MH organization or MH hotline in China, like the European Malignant Hyperthermia Group (EMHG) or the Malignant Hyperthermia Association of the United States (MHAUS), the great difficulties to obtain expert guidance from professionals in MH emergency worsen the situations.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Features of Suspected Malignant Hyperthermia in China from 2015 to 2020: A Retrospective Study from China Malignant Hyperthermia Emergency Assistance Group

Tan

Teng

et al. 2022

JMDH

Self Cite

View full text Add to dashboard Cite

Malignant hyperthermia (MH) is a rare but fatal pharmacogenetic disorder, triggered by inhalational anesthetics or succinylcholine. Since the first nonprofit academic organization China Malignant Hyperthermia Emergency Assistance WeChatbased Group (CMHEA Group) was established in 2015, they have actively participated in the diagnosis and treatment of MH patients. Based on the CMHEA Group, the aim of the study was to retrospectively analyze the characteristics of suspected MH in China from 2015 to 2020. Methods: We conducted a retrospective analysis of the suspected MH patients from 2015 to 2020, for analyzing the current clinical diagnosis, treatment and prognosis of MH in China.Results: A total of 58 suspected MH cases occurred from 2015 to 2020, of these, 36 cases were collected with detailed data. The MH clinical grading score of 36 patients ranged from 33 to 73, with a median of 55. Abnormal hyperthermia and hypercarbia were the most common early signs of MH. Four patients were confirmed carrying six different potential MH-causative mutations. Of the total 58 cases, 14 patients (24.1%) received dantrolene and the whole mortality rate was 53.4%. Compared to the patients not receiving dantrolene treatment, the survival rate of patients receiving dantrolene treatment was significantly higher than that of patients not receiving dantrolene (78.6% vs 36.4%, p = 0.007). Conclusion:The current main diagnostic methods of suspected MH in China are still clinical diagnosis. Hence, it is critical to keep dantrolene for immediate accessibility with the introduction of domestic dantrolene to China. The WeChat group model has played an important but limited role in quick diagnosis and treatment of MH.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Clinical Features of Suspected Malignant Hyperthermia in China from 2015 to 2020: A Retrospective Study from China Malignant Hyperthermia Emergency Assistance Group

Tan

Teng

et al. 2022

JMDH

Self Cite

View full text Add to dashboard Cite

show abstract

“…Anesthesiologists need to recognize it in its early stages and begin appropriate management without any delay [ 7 ]. In China, there has been increased recognition and publication of MH cases in recent years [ 8 - 10 ]. Over the past 35 years, a reported total of 136 MH events occurred in mainland China according to data from the nonprofit academic organization China MH Emergency Assistance Group [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

“…Over the past 35 years, a reported total of 136 MH events occurred in mainland China according to data from the nonprofit academic organization China MH Emergency Assistance Group [ 11 ]. However, knowledge about the recognition and management of MH is still lacking among anesthesiologists [ 8 ]. The mortality rate of MH was as high as 55.9% [ 11 ], which was similar to the range reported in the pre-dantrolene era in the United States [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The First National Remote Emergency System for Malignant Hyperthermia (MH-NRES) in China: Protocol for the Design, Development, and Evaluation of a WeChat Applet

Yu¹,

Tan²,

Teng³

et al. 2022

JMIR Res Protoc

Self Cite

View full text Add to dashboard Cite

Background Malignant hyperthermia (MH) is a rare life-threatening anesthetic emergency. With respect to the high fatality rate, difficulty in early recognition, and the lack of disease-specific drug (ie, dantrolene) in China, more effort is needed to strengthen early diagnosis and effective treatment of MH emergencies. Nowadays, mobile health (mHealth) apps are changing the way of medical practice; they can serve as an accessible tool to help anesthesiologists deal with MH crises. However, no related mHealth-based emergency system is available currently. Objective The aim of this study is to outline the protocol for the development of a WeChat applet used to design a National Remote Emergency System for Malignant Hyperthermia (MH-NRES) in China, as well as the protocol for the evaluation of the user experience and perception of the system. Methods The system adopts the client-server architecture, with a custom user interface operating as clients and the back-end system operating as the server. The client-side software was developed using uni-app technology with Vue.js-based framework, which consists of 6 modules: Quick Diagnosis, Dantrolene Mobilization, Instruction on Dantrolene Use, MH Treatment, Recovery Period Treatment, and DNA Test and Biopsy. The back-end system was developed based on the Spring framework. The system will be evaluated by administrating a modified user version of the Mobile App Rating Scale. Pilot testing will be conducted in Sichuan Province, China, and a subsequent evaluation on a national scale is planned. Results The theoretical framework design of this system was completed in August 2021. The development of the system was completed in February 2022, and the refinement is currently ongoing. Pilot testing after the implementation of the system in Sichuan Province is planned to take 2 months, and the subsequent evaluation on a national scale is planned to take 2 months. Conclusions We have described a novel approach using the WeChat applet to develop the MH-NRES. Findings from the usability testing process in the current study may lead to refinements and is expected to suggest that this system is both feasible and welcomed by anesthesiologists. Depending on the availability of research funding, this system will be extended nationally across China. International Registered Report Identifier (IRRID) PRR1-10.2196/37084

show abstract

Suspected malignant hyperthermia in a young Chinese patient undergoing a micro varicocelectomy surgery

Wang

Peng

et al. 2023

Chinese Medical Journal

View full text Add to dashboard Cite

Malignant Hyperthermia Status in China

Cited by 8 publications

References 20 publications

Clinical Features of Suspected Malignant Hyperthermia in China from 2015 to 2020: A Retrospective Study from China Malignant Hyperthermia Emergency Assistance Group

Clinical Features of Suspected Malignant Hyperthermia in China from 2015 to 2020: A Retrospective Study from China Malignant Hyperthermia Emergency Assistance Group

The First National Remote Emergency System for Malignant Hyperthermia (MH-NRES) in China: Protocol for the Design, Development, and Evaluation of a WeChat Applet

Suspected malignant hyperthermia in a young Chinese patient undergoing a micro varicocelectomy surgery

Contact Info

Product

Resources

About